Browse GPR68

Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Proton-sensing receptor involved in pH homeostasis. May represents an osteoblastic pH sensor regulating cell-mediated responses to acidosis in bone. Mediates its action by association with G proteins that stimulates inositol phosphate (IP) production or Ca(2+) mobilization. The receptor is almost silent at pH 7.8 but fully activated at pH 6.8. Function also as a metastasis suppressor gene in prostate cancer (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001678 cellular glucose homeostasis
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002793 positive regulation of peptide secretion
GO:0009268 response to pH
GO:0009306 protein secretion
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009914 hormone transport
GO:0010720 positive regulation of cell development
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030099 myeloid cell differentiation
GO:0030224 monocyte differentiation
GO:0030316 osteoclast differentiation
GO:0032024 positive regulation of insulin secretion
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0033500 carbohydrate homeostasis
GO:0034284 response to monosaccharide
GO:0035773 insulin secretion involved in cellular response to glucose stimulus
GO:0035774 positive regulation of insulin secretion involved in cellular response to glucose stimulus
GO:0036035 osteoclast development
GO:0042593 glucose homeostasis
GO:0042886 amide transport
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045655 regulation of monocyte differentiation
GO:0045656 negative regulation of monocyte differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045672 positive regulation of osteoclast differentiation
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046887 positive regulation of hormone secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0060348 bone development
GO:0061178 regulation of insulin secretion involved in cellular response to glucose stimulus
GO:0061515 myeloid cell development
GO:0071214 cellular response to abiotic stimulus
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0071467 cellular response to pH
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0090277 positive regulation of peptide hormone secretion
GO:0098751 bone cell development
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903010 regulation of bone development
GO:1903012 positive regulation of bone development
GO:1903131 mononuclear cell differentiation
GO:1903532 positive regulation of secretion by cell
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1904951 positive regulation of establishment of protein localization
GO:2001204 regulation of osteoclast development
GO:2001206 positive regulation of osteoclast development
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GPR68 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between GPR68 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23222714Prostate CarcinomaInhibit immunityIn summary, the expression of OGR1 in myeloid-derived cells, especially in DP cells, was required for PCa tumor cell-induced immunosuppression.
Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GPR68 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GPR68 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9510.0954
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.510.268
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5210.544
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3760.417
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.130.937
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0190.633
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4230.47
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5990.518
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1810.859
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.7940.0315
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.2610.0556
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2450.285
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GPR68 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GPR68. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GPR68. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GPR68.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GPR68. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GPR68 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GPR68 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGPR68
NameG protein-coupled receptor 68
Aliases OGR1; GPR12A; G-protein coupled receptor 68; ovarian cancer G protein-coupled receptor, 1; sphingosylphospho ......
Chromosomal Location14q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GPR68 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.